ClinicalTrials.gg
RecruitingNCT07413965BELIEVERSUpdated Aug 14, 2026

TAVR vs SAVR in Severe Bicuspid Aortic Stenosis

An interventional study of Transcatheter Aortic Valve Replacement and the open chest surgery to replace the aortic valve in Bicuspid Aortic Valve Disease, sponsored by Cedars-Sinai Medical Center. Recruiting at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Cedars-Sinai Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Bicuspid Aortic Valve Disease with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Bicuspid Aortic Valve Disease · United States.

Started
2026
the only one that year
No phase
7 of 19
2 open now
Registered
19th of 19
by date
Lead sponsor
3 of 19
Cedars-Sinai Medical Center

Among the 19 studies in Bicuspid Aortic Valve Disease with a site in United States, this one is the only one that started in 2026, is one of 7 with no phase, and was the 19th registered.

Bicuspid Aortic Valve Disease

62 studies on the registry are indexed under Bicuspid Aortic Valve Disease; 21 are open to participants now.

Browse Bicuspid Aortic Valve Disease studies →

Open to participants now

6 of the 19 studies in Bicuspid Aortic Valve Disease with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Bicuspid Aortic Valve Disease studies recruiting now, 12 (71%) set no upper age limit and 3 (18%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Bicuspid Aortic Valve Disease with a site in United States, or all of them as a file.
02

Study summary

The study is a multicenter, randomized superiority trial of standard of care therapies for severe aortic stenosis (AS) in patients with a bicuspid aortic valve (BAV).

The two primary comparators in this study are: Transcatheter Aortic Valve Replacement (TAVR), and Surgical Aortic Valve Replacement (SAVR).

TAVR is a minimally invasive transcatheter procedure to treat aortic valve disease..

SAVR is involving the open chest surgery to replace the aortic valve.

The devices and international procedures in this Trial (TAVR or SAVR) are commercially approved by the FDA.

Consented patients who are qualifying for the Trial will be randomized 1:1, meaning they will have an equal chance to be treated with either TAVR or SAVR procedure.

Consented patients who will not qualify for the randomized part of the study will be followed up clinically in either TAVR or SAVR Registry arms.

The study objective is to provide evidence to guide patients and their providers on the most appropriate therapy for valve replacement on this particular BAV anatomy.

Read the detailed description

Bicuspid aortic valve is a congenital heart condition characterized by the presence of two, rather than the typical three, cusps in the aortic valve.

The condition can lead to various complications, including aortic stenosis (AS; narrowing of the valve opening), aortic regurgitation (leaking of the valve), and an increased risk of aortic aneurysm.

The BELIEVERS trial builds on this foundation, integrating imaging-guided methodologies to create a robust framework for randomization with contemporary technologies and thus provide definitive evidence for treatment of this complex population.

Since the congenital severe bicuspid aortic valve stenosis was considered in most of the cases an exclusion from all large TAVR vs SAVR trials, there is no clear evidence on which procedure would be more efficient for such anatomical condition.

The suitable consented subjects will be randomized 1:1 on either TAVR or SAVR arm. These patients will be followed through clinic visits at 30 days, one year and annually up to 10 years.

03

Conditions studied

  • Bicuspid Aortic Valve Disease

Keywords

  • Severe Bicuspid Aortic Valve intervention: TAVR vs SAVR
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 50 years of age or older at time of consent
  2. Severe AS deemed suitable for a bioprosthesis by a local heart team (unsuitable or patient declined a mechanical valve or Ross procedure, following demonstration of evidence-based shared decision making with a validated decision-aid(1)
  3. Gated contrast CT available and suitable for core laboratory analysis;
  4. BAV anatomy confirmed by CT core laboratory analysis

Exclusion criteria

Exclusion Criteria:

  1. Recent cardiovascular intervention within 30 days prior to randomization.
  2. Presence of an existing TAVR or SAVR device
  3. Pregnancy or lactation
  4. Extreme or prohibitive TAVR or SAVR risk, adjudicated by Patient Selection Committee (PSC) Review
  5. Active enrollment in another study
  6. Disproportionate TAVR vs SAVR risk, as adjudicated by the patient selection committee
  7. Associated aortopathy (AA≥45mm by maximal cross-sectional dimension, as confirmed by CT core laboratory analysis, or AA\<45mm but site plan for surgery of the aorta in the event of randomization to surgery
  8. Site plan for treatment of concomitant non-coronary cardiovascular disease in the event of randomization to surgery (for instance, concomitant valve surgery, septal defect or coarctation repair, aorta or root replacement or repair)
  9. In the presence of coronary artery disease deemed necessary for revascularization in the event of randomization to SAVR or TAVR, Syntax score ≥ 32 or deemed unsuitable for PCI, or deemed unsuitable for coronary artery bypass grafting (CABG)
  10. Plan to use any device other than commercially approved Edwards balloon expandable or Medtronic self-expanding TAVR
  11. Leukopenia (WBC \< 3000 cells/µL), anemia ( \< 8 g/dL), Thrombocytopenia (Plt \< 50,000 cells/µL) on latest available labs within 30 days prior to randomization
  12. Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation, or mechanical heart assistance within 30 days prior to randomization
  13. \< 25% within 90 days prior to randomization
  14. Stroke or (TIA) within 90 days prior to randomization
  15. Renal insufficiency ( \< 30 ml/min per the formula)
  16. Severe lung disease ( \< 50% predicted), unresolved prior to randomization
  17. History of liver disease defined as MELD Score ≥ 10 or Class B or C
  18. Unable to complete the KCCQ due cognitive impairment or other medical condition
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,200 participants (estimated)

Study arms

  • Other
    Transcatheter Aortic Valve Replacement TAVR

    percutaneous approach as modality of treatment

    Procedure: Transcatheter Aortic Valve Replacement

  • Active comparator
    Surgical Aortic Valve Replacement SAVR

    open chest approach as modality of treatment

    Procedure: the open chest surgery to replace the aortic valve

Interventions

  • ProcedureTranscatheter Aortic Valve Replacement

    This is a transcatheter, percutaneous approach using the commercially approved bioprosthetic valve device to replace the diseased aortic valve

  • Procedurethe open chest surgery to replace the aortic valve

    This is the open chest surgical approach using the commercially approved bioprosthetic valve device to replace the diseased aortic valve

06

What researchers measure

Primary outcomes

  1. To compare the safety and effectiveness of TAVR vs SAVR for the treatment of severe AS in patients with BAV

    A hierarchical composite (assessed by Win ratio at latest available follow-up) of: 1. death, 2. disabling stroke, 3. non-disabling stroke, 4. valve reintervention, 5. rehospitalization†, 6. unfavorable KCCQ (VARC-3\*)

    Time frame: 2 years post end of enrollment

Secondary outcomes

  1. Time-averaged KCCQ

    time-weighted mean of KCCQ overall summary score across at follow-up timepoints

    Time frame: 3 years post end of enrollment

  2. KCCQ status (serial)

    overall summary score at discharge and specified follow-up visits

    Time frame: at 2 years post end of enrollment

  3. SF-12 questionnaire

    physical and mental component summary scores at prespecified visits.

    Time frame: at 2 years post end of enrollment

  4. NYHA class

    NYHA I-IV at prespecified visits

    Time frame: at 2 years post end of enrollment

  5. 6-minute walk test

    distance (meters) at prespecified visits.

    Time frame: at 2 years post end of enrollment

  6. PHQ-9 questionnaire

    depression score (0-27) at prespecified visits

    Time frame: at 2 years post end of enrollment

  7. Time-to-recovery to baseline (QOR-15)

    time from index procedure to first follow-up at which QOR-15 returns to (or exceeds) the participant's pre-procedure baseline (operational rules and handling of missingness specified in SAP).

    Time frame: at 2 years post end of enrolment

  8. Additional clinical time-to event endpoints

    death (time-to-first event) and cardiovascular death (time-to-fist event),•All stroke, disabling stroke (time-to-first event). • Rehospitalization (time-to-first event), • Composite of death/stroke/rehospitalization: time to first occurrence of any of death, any stroke, or qualifying rehospitalization. • Aortic dissection: imaging-, operative-, or autopsy-confirmed aortic dissection after randomization. • Need for surgery of the aorta: • CV rehospitalization days

    Time frame: at 2 years post end of enrollment

  9. Secondary Imaging Endpoints

    Echocardiography Core Lab• Bioprosthetic valve failure (BVF): • Paravalvular leak (PVL) severity:

    Time frame: at 2 years post end of enrollment

  10. Secondary Imaging Endpoints CT

    Ascending aorta dimension \>50 mm: maximum ascending aorta diameter measured by CT Core Lab; endpoint met if \>50 mm at any follow-up CT• Change in ascending aorta dimension (cm/year): annualized change in maximum ascending aorta diameter from baseline to follow-up CT by CT Core Lab.

    Time frame: at 2 years post end of enrollment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jul 2032, 71 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2026
First posted
Feb 17, 2026
StartActual
Jul 23, 2026
Primary completionEst.
Jul 1, 2032
CompletionEst.
May 10, 2040
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07413965
Collaborators
Patient-Centered Outcomes Research Institute, Icahn School of Medicine at Mount Sinai, Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Responsible party
Raj Makkar (Principal Investigator, Cedars-Sinai Medical Center) — Principal investigator
First posted
Feb 17, 2026
Start date
Jul 23, 2026
Primary completion
Jul 1, 2032 (estimated)
Completion
May 10, 2040 (estimated)
Last update
Aug 14, 2026

Study contacts

Raj Makkar, MD
principal investigator · Cedars-Sinai Medical Center
Marcio Diniz, PhD
principal investigator · Icahn School of Medicine at Mount Sinai
Vinod Thourani, MD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion